36405-72-8

Upstream product

• 874-61-3 4-oxocyclohexanecarboxylic acid 
• 13815-62-8 N¹-(4-Chlorbenzoyl)-N¹-(4-methoxyphenyl)hydrazin-hydrochlorid 
• 16205-98-4 3-oxo-cyclohexanecarboxylic acid 
• 13815-71-9 1-ethylidene-2-(4-methoxyphenyl)hydrazine 
• 13815-59-3 Acetaldehyd-N₁-(p-chlorbenzoyl)-p-methoxy-phenylhydrazon 
• 122-01-0 4-chloro-benzoyl chloride 
• 74-88-4 methyl iodide 
• 17159-79-4 ethyl 4-oxocyclohexane-1-carboxylate 
• 52068-30-1 4-benzyloxyphenylhydrazine hydrochloride 

Downstream Products

• 1427215-14-2 C₂₂H₂₁ClN₂O₅S 

Relevant academic research and scientific papers

Discovery of tetrahydrocarbazoles with potent hypoglycemic and hypolipemic activities

A series of tetrahydrocarbazole derivatives was designed and synthesized on the basis of the AMP-activated protein kinase activator GY3. All the synthesized compounds were screened in HepG2 cell lines for glucose consumption activity and several of them showed potent glucose decreasing activity. In vivo evaluation of the hypoglycemic and hypolipemic effects indicated that 7a exhibited comparable activity with pioglitazone, but with a weaker body-weight increasing effect. The pharmacokinetic profiles of 7a were also investigated.

Development of potent and selective indomethacin analogues for the inhibition of AKR1C3 (type 5 17β-hydroxysteroid dehydrogenase/prostaglandin F synthase) in castrate-resistant prostate cancer

Castrate-resistant prostate cancer (CRPC) is a fatal, metastatic form of prostate cancer. CRPC is characterized by reactivation of the androgen axis due to changes in androgen receptor signaling and/or adaptive intratumoral androgen biosynthesis. AKR1C3 is upregulated in CRPC where it catalyzes the formation of potent androgens. This makes AKR1C3 a target for the treatment of CRPC. AKR1C3 inhibitors should not inhibit AKR1C1/AKR1C2, which inactivate 5α-dihydrotestosterone. Indomethacin, used to inhibit cyclooxygenase, also inhibits AKR1C3 and displays selectivity over AKR1C1/AKR1C2. Parallel synthetic strategies were used to generate libraries of indomethacin analogues, which exhibit reduced cyclooxygenase inhibitory activity but retain AKR1C3 inhibitory potency and selectivity. The lead compounds inhibited AKR1C3 with nanomolar potency, displayed >100-fold selectivity over AKR1C1/AKR1C2, and blocked testosterone formation in LNCaP-AKR1C3 cells. The AKR1C3·NADP +·2′-des-methyl-indomethacin crystal structure was determined, and it revealed a unique inhibitor binding mode. The compounds reported are promising agents for the development of therapeutics for CRPC.

9-Acyl-1,2,3,4-tetrahydrocarbazole-3 and 4-carboxylic acids

Novel 9-aroyl-1,2,3,4-tetrahydrocarbazoles bearing a carboxy substituent at position 3 or 4 and corresponding esters having antiinflammatory activity, the preparation thereof and novel intermediates therefor are described.